Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009

MOUNTAIN VIEW, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News) announced today that it will release results for the quarter ended September 30, 2009 on Monday, November 9, 2009, following the close of the U.S. financial markets. The Company will host an investor conference call at 5:00 p.m. Eastern Time on the same day to discuss these third quarter results. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties. To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PNPXXM88G.To access the live conference call via phone, dial 888-680-0890. International callers may access the live call by dialing 617-213-4857. The reference numb...
Click here to read the whole Article (external link)

ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events

Item 8.01 Other Events. In February 2009, the Board of Directors (the "Board") of Alexza Pharmaceuticals, Inc. (the "Company"), based upon the approval and recommendation of the Compensation Committee of the Board (the "Committee"), approved the adoption of the Company's 2009-2010 Performance Based Incentive Program (the "Performance Program") for the Company's employees, including its executive officers. The Performance Program is a two-year incentive program that was adopted to motivate and retain the Company's employees. The Performance Program was adopted in lieu of the Company's annual performance bonus programs that it had previously used in 2006, 2007 and 2008, annual salary merit increases for 2009 and annual refresh option grants typically granted to employees with more than 24 months of service. The Performance Program was adopted to encourage Company employees to focus on two key deliverables for the next 24 months, and to allow the Company to conserve cash resources by utilizing equity compensation as a major component of this program. Payouts (stock options, restricted stock units and/or cash) under the Performance Program are contingent upon the achievement of two specified corporate milestones related to the submission and approval of a New Drug Application for the Company's AZ-004 (Staccato® loxapine) product candidate (the "AZ-004 NDA"). Also in February 2009, the Board granted restricted stock units ("RSUs") to all of its employees, including its executive officers, pursuant to the Performance Program. The following executive officers of the Company received an RSU grant on such date: Thomas B. King, President and Chief Executive Officer; August J. Moretti, Senior Vice President and Chief Financial Officer; James V. Cassella, Ph.D., Senior Vice President, Research and Development; and Michael J. Simms, Senior Vice President, Operations and Manufacturing (each, an "executive officer"). These RSUs will ...
Click here to read the whole Article (external link)

Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference

MOUNTAIN VIEW, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News) announced today that company management will present a corporate overview during the Fourth Annual JMP Securities Healthcare Focus Conference, being conducted at the New York Palace Hotel in New York. This corporate overview will be webcast live on Tuesday, October 6, 2009 at 10:30 a.m. Eastern Time. To access the live presentation via the Web, please go to the direct conference link located at www.wsw.com/webcast/jmp9/alxa/ or at the Alexza Investor Relations tab at www.alexza.com.A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.About Alexza Pharmaceuticals, Inc.Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapi...
Click here to read the whole Article (external link)

Alexza Reports 2009 Third Quarter Financial Results and Updates AZ-004 (Staccato(R) Loxapine) NDA Status

MOUNTAIN VIEW, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News) reported today financial results for the quarter ended September 30, 2009, and provided a status update of its AZ-004 New Drug Application (NDA). The net loss for the three and nine months ended September 30, 2009, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.4 million and $36.3 million, respectively, compared to a net loss of $20.8 million and $59.1 million in the comparable periods in 2008, respectively. Alexza had consolidated cash, cash equivalents and marketable securities at September 30, 2009 of $14.7 million. In October 2009, Alexza issued an aggregate of 8,107,012 shares of its common stock and warrants to purchase up to an additional 7,296,312 shares of its common stock in a private placement. These securities were sold as units with each unit consisting of one share of common stock and a warrant to purchase 0.9 shares of common stock at a purchase price of $2.4325 per unit. The net proceeds, after deducting the payment of a placement agent fee and other offering expenses, were approximately $19.1 million. The warrants issued are cash or net exercisable for a period of seven years from October 5, 2009 and have an exercise price of $2.77 per share."During the third quarter, we completed all of the planned clinical work for our AZ-004 NDA and completed the purchase of Symphony Allegro to reacquire the full ownership of AZ-004, along with AZ-104 ...
Click here to read the whole Article (external link)

Q3 2009 ALEXZA PHARMACEUTICALS INC Earnings Release - After Market Close

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript

Alexza Pharmaceuticals, Inc. (ALXA) Q3 2009 Earnings Call November 9, 2009 5:00 AM ET Executives August J. Moretti – Senior Vice President and Chief Financial Officer Thomas King – President and Chief Executive Officer Analysts Ted Tenthoff – Piper Jaffray Jason Kantor – RBC Capital Markets Presentation Operator Good afternoon, everyone, and welcome to the Alexza Pharmaceuticals 2009 third quarter financial results conference call. (Operator Instructions). I would now like to turn this afternoon’s conference over to August J. Moretti, Senior Vice President and Chief Financial Officer of Alexza. August Moretti Welcome to today’s conference call. Before we get started, I’d like to remind you that the matters discussed on this call contain forward-looking statements that involve and uncertainties including those related to the potential results of future clinical development, our ability to commercialize products, the timing of the commercialization of such products, and our projected revenues, expenses, and cash requirements. Actual results may differ materially from the results predicted, and recorded results should not be considered an indication of future performance. These and other risk factors are more fully discussed in our annual report on Form 10-K which we filed with the SEC in March and our quarterly report on Form 10-Q which we filed with the SEC earlier today, most particularly under the caption of risk factors in both reports. Alexza disclaims any obligatin to update or revise any forward-looking statements made on this cal...
Click here to read the whole Article (external link)

Alexza Pharmaceuticals Inc. Earnings Call scheduled for 5:00 pm ET today

Call DetailsAlexza Pharmaceuticals Inc. Earnings Conference Call (Q3 2009)Mon, Nov 9, 2009, 5:00 pm EasternAbout Alexza Pharmaceuticals Inc. (NasdaqGM:ALXA)Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches. Its products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company’s single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to ...
Click here to read the whole Article (external link)

ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for ALEXZA PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ALEXZA PHARMACEUTICALS INC. 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for infor...
Click here to read the whole Article (external link)

Alexza Pharmaceuticals CEO Interview With The Wall Street Transcript

67 WALL STREET, New York - November 11, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); N...
Click here to read the whole Article (external link)

ALEXZA PHARMACEUTICALS INC. Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)